Study of lipid profile for psoriatic patients in AL-Anbar governorate. | ||
| Journal of University of Anbar for Pure Science | ||
| Article 33, Volume 7, Issue 2, August 2013, Pages 1-7 PDF (459.79 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.37652/juaps.2013.84989 | ||
| Authors | ||
| Wajeeh Y. Mohammed* 1; Abdullah S. Al-Hasan2; Ausama A. Faisal3 | ||
| 1University Of Anbar - College of science | ||
| 2University Of Anbar - College of medicine | ||
| 3University of Anbar - College of Medicine | ||
| Abstract | ||
| Psoriasis is a chronic inflammatory skin condition which affects approximately 1-3% of the world's population (1). It appears as red plaques covered with silvery scale that flakes away from the skin.Psoriatic plaques are often found on the elbows, scalp and knees but can also affect other parts of the body such as the face, feet and mucous membranes.Psoriasis is not contagious, nor is it caused by an allergy. However, the tendency to develop the condition can be genetically transmitted. Psoriasis causes itching in 60% to 70% of cases (2). However, the exact etiology of psoriasis is unknown. Abnormalities in lipid metabolism have been proposed because the abnormalities in lipids lead to abnormalities in skin formation which is made from lipids. To evaluate the serum lipids profile in psoriatic patients of Al-Anbar governorate and to compare the results with other external studies. The study group included 60 patients with psoriasis, and 30 healthy volunteers. Blood lipid profile was determined using commercial kits from reliable French and Spain companies. All patients had psoriasis involving less than 30% of body surface. Their ages ranged from 10 to 60 years with a mean of 32 years. Family history of psoriasis was positive in a percentage of (20%) of the patients. The mean levels of serum lipids (total cholesterol, triglyceride, low density lipoprotein, and very low density lipoprotein) in patients with psoriasis were found to be significantly higher than those of healthy individuals. The mean levels of high density lipoprotein were not significant. This study strengthens the relationship between the lipids intake, formation, and metabolism with the pathogenesis of psoriasis. Therefore it is concluded that psoriatic patients should be evaluated for hyperlipidemia and obstructive vascular diseases. Administrating lipid-lowering medicines for patients particularly cases with severe disease may be beneficial prognosis. | ||
| Keywords | ||
| psoriasis; triglyceride; VLDL; HDL; LDL; and Cholesterol | ||
| References | ||
|
(1) Schon, N 2005 psoriasis general concepts, Engl J Med.
(2) Sampogna, Br 2004 psoriasis etiopathogenesis, J dermatol.
(3) Icen M., Crowson C. S., McEvoy M. T., et al. 2009 “Trends in incidence of adult-onset psoriasis over three decades: a population-based study,” Journal of the American Academy of Dermatology, vol. 60, no. 3, 394–401.
(4) Wilson F. C., Icen M., Kremers H. M., 2009 “Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study,”Arthritis Care and Research, vol. 61, no. 2, 233–239.
(5) Chandran V.and Raychaudhuri S. P., 2010 “Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis,” Journal of Autoimmunity, vol. 34, no. 3, 314–321.
(6) Romanowska M., and Al Yacoub, N. 2008 “PPARδ enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor,” Journal of Investigative Dermatology, vol. 128, no. 1, 110–124.
(7) Chen Y.-J., Shen J.-L., and Lee F.-Y., 2009 “Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 60, no. 2, 225–230.
(8) Chibowska M., 1970 “Role of serum lipids in psoriasis,” Przeglad Dermatologiczny, vol. 57, no. 2, 255–260.
(9) Pietrzak A., Toruniowa B., and J. Chwaluk, 1994 “Lipid profile in psoriatic patients according to sex and age,” Przeglad Dermatologiczny, vol. 81, no. 5, 441–449.
(10) Jungersted J.M., Hellgren L. I., and T. Agner, 2008 “Lipids and skin barrier function—a clinical perspective,” Contact Dermatitis, vol. 58, no. 5, 255–262,.
(11) Bleck O., Abeck D., Ring J. et al., 1999 “Two ceramide subfractions detectable in Cer(AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema,” Journal of Investigative Dermatology, vol. 113, no. 6, 894–900.
(12) Landmann L., 1986 “Epidermal permeability barrier: transformation of lamellar granule-disks into intercellular sheets by a membrane-fusion process, a freeze-fracture study,” Journal of Investigative Dermatology, vol. 87, no. 2, 202–209.
(13) Elias P. M. and Menon G. K., 1991 “Structural and lipid biochemical correlates of the epidermal permeability barrier,” Advances in Lipid Research, vol. 24, 1–26.
(14) Grayson S. and Elias P. M., 1982 “Isolation and lipid biochemical characterization of stratum corneum membrane complexes: implications for the cutaneous permeability barrier,” Journal of Investigative Dermatology, vol. 78, no. 2, 128–135,.
(15) Man M. Q. M., Feingold K. R., and P. M. Elias, 1996 “Optimization of physiological lipid mixtures for barrier repair,” Journal of Investigative Dermatology, vol. 106, no. 5, 1096–1101.
(16) Holleran W. M., Feingold K. and P. M. Elias, 1991 “Regulation of epidermal sphingolipid synthesis by permeability barrier function,” Journal of Lipid Research, vol. 32, no. 7, 1151–1158.
(17) Motta S., Monti and Caputo R ., 1994 “Abnormality of water barrier function in psoriasis: role of ceramide fractions,” Archives of Dermatology, vol. 130, no. 4, 452–456.
(18) Ghadially R., Reed J. T., and Elias P. M., 1996 “Stratum corneum structure and function correlates with phenotype in psoriasis,” Journal of Investigative Dermatology, vol. 107, no. 4, 558–564.
(19) Khyshiktuev B. S. and Falko E. V., 2005 “Alterations in the parameters of lipid metabolism in different biological objects in psoriatic patients during exacerbation and remission,” Vestnik Dermatologii i Venerologii, vol. 6, 40–43.
(20) Ansidei V., Binazzi M., Cantelmi A., Gaiti A., and Porcellati G., 1981 “Phospholipid involvement in psoriatic epidermis,” Italian Journal of Biochemistry, vol. 30, no. 1, 40–45.
(21) Buccolo G. et al. 1973 Quantitativedetermination of serum triglycerides by use enzymes. Clin. Chem; 19(5): 476-482.
(22) Naitoh H.K. Kaplan A et al. 1984 cholesterol , clin chem. The C.V. Mosby Co. St Louis. Toronto. Princeton1194-11206 and 437.
(23) OrtonneJP. 1999 Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol,140:1-7.
(24) Neimann AL, Shin DB, Wang X, et al. 2006 Prevalence of cardiovascular risk factors in patients with psoriasis. J Amer Acad Dermatol, 55:829-835.
(25) Cohen AD, Sherf M, Vidavsky L, et al. 2008 Association between psoriasis and the metabolic syndrome. Dermatol, 216:152-155.
(26) Alobaidi A. H. Ahmad, 2006 Biochemical Changes in Psoriasis Lipid Profile, Oxidant and Antioxidant Markers. J med. Vol. 3 Issue 1.
(27) Akhyani M, Ehsani AH, Robati RM, Robati AM. 2007 The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol, 21:1330-1332.
(28) Solak Tekin N, Tekin IO, Barut F, Sipahi EY. 2007 Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflam, 1-5. | ||
|
Statistics Article View: 256 PDF Download: 92 |
||